JDRF Partner ViaCyte to Immediately Initiate Type 1 Diabetes Clinical Trial

Updated Sept. 18, 2014 JDRF’s partner ViaCyte recently announced the U.S. Food and Drug Administration (FDA) is allowing them to move forward with a clinical trial of its innovative type 1 diabetes (T1D) encapsulated cell replacement therapy called VC-01™ product candidate. The company plans to immediately initiate the first ever clinical evaluation of a stem […]

Oxygen – A Key Ingredient of Life

JDRF partners with Beta-O2 Technologies to develop a novel implantable encapsulation device for type 1 diabetes The dream for everyone with type 1 diabetes (T1D) is to permanently restore their body’s lost ability to produce insulin. This defines a cure for T1D and remains a top priority for JDRF. As we work towards this longer-term […]

Rebalancing the Immune System

Novel therapy to increase beneficial immune cells shows promise in pilot type 1 diabetes clinical study Type 1 diabetes (T1D) is caused when a person’s immune system mistakenly destroys their insulin-producing beta cells. How and why this misguided attack begins remains a mystery, but JDRF research has helped shed light on the disease process, opening […]

Potential Breakthrough in Encapsulation Technology

JDRF-funded researchers develop novel method of protecting islets for implantation into people with type 1 diabetes Pancreatic islet transplantation has restored insulin independence in some individuals with type 1 diabetes (T1D), but the procedure is not widely available due to the limited supply of donated islets and the need for strong immunosuppressive drugs to prevent […]

Cocktail Immune Therapy Beats Going Solo

New clinical results show positive effect of combination immune therapy for type 1 diabetes Type 1 diabetes (T1D) is caused when the immune system mistakenly attacks insulin-producing beta cells within the pancreas. While there have been numerous clinical studies using general immunotherapy to stop or slow the T1D attack, researchers have been generally disappointed with […]

Changing the Standard Management of Type 1 Diabetes

Adding novel therapy to an insulin regimen may allow for better glucose control and reduced insulin dosages Before insulin was discovered in 1921, people with type 1 diabetes (T1D) didn’t live very long. Its discovery was a great breakthrough and saved lives, but since then the basic management of T1D has continued to remain focused […]

A Difficult Journey from the Lab to People with Type 1 Diabetes

New study highlights the challenges of translating promising research to effective treatments Results from a clinical study in people with type 1 diabetes (T1D) who were treated with a combination of two drugs in an attempt to improve their beta cell survival and stimulate beta cell regeneration are so far inconclusive. The study, called REPAIR-T1D […]

Top 10 Advances in T1D Research

JDRF-supported progress in fiscal year 2014 JDRF sets ambitious goals for progress in type 1 diabetes (T1D) research each year because our supporters inspire us to aim higher. We invite you to read about the real impact our strategic plan is making and hope you are as inspired as we are as each of these […]

Next-Generation Artificial Pancreas System Gears Up for Test Drive

Pilot study will evaluate advanced artificial pancreas technology under real-world situations For several years, JDRF-funded researchers at the University of Virginia Center for Diabetes Technology have been hard at work designing an artificial pancreas system that would allow individuals with type 1 diabetes (T1D) to go about their daily lives and sleep through the night […]

JDRF Ranked as Top Non-Governmental Diabetes Research Funder

Independent analysis of key scientific literature found JDRF among the top organizations funding diabetes research globally In a recent independent analysis of key diabetes-related scientific literature, JDRF was ranked as the third most frequently cited funder of diabetes research globally, behind only the U.S. National Institutes of Health and the National Natural Science Foundation of […]